ArticlePloS one2017
Blood type, ABO genetic variants, and ovarian cancer survival.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes.Frontiers in medicine · 2026Review
- ABO exon polymorphisms are related to ischemic stroke in a Chinese Han population.BMC medical genomics · 2025Article
- Association of blood group types and clinico-pathological features of gynecological cancers (GCs).BMC cancer · 2025Article
- Investigation of unfavorable prognostic factors for survival in Chinese patients with gastric gastrointestinal stromal tumors.Translational cancer research · 2024Article
- Differential expression ofJournal of Taibah University Medical Sciences · 2024Article
- Prevalence and distribution of serological characteristics of weak ABO subgroups in the Chinese population.Hematology, transfusion and cell therapy · 2024Article
- Enhancing genetic association power in endometriosis through unsupervised clustering of clinical subtypes identified from electronic health records.Research square · 2024Article
- Genome-wide association study of serum tumor markers in Southern Chinese Han population.BMC cancer · 2022Article
- Assessment of gynecological and lifestyle-related risk factors of ovarian cancer.Przeglad menopauzalny = Menopause review · 2021Article
- Individuals with a Rh-positive but not Rh-negative blood group are more vulnerable to SARS-CoV-2 infection: demographics and trend study on COVID-19 cases in Sudan.New microbes and new infections · 2020Article
- ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity.Oncology letters · 2018Article
- ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer.Journal of Cancer · 2018Article
- Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.Therapeutics and clinical risk management · 2018Article
- Article
- Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
objectiveBlood type A and the A1 allele have been associated with increased ovarian cancer risk. With only two small studies published to date, evidence for an association between ABO blood type and ovarian cancer survival is limited.
methodsWe conducted a retrospective cohort study of Tumor Registry confirmed ovarian cancer cases from the Vanderbilt University Medical Center with blood type from linked laboratory reports and ABO variants from linked Illumina Exome BeadChip data. Associations with overall survival (OS) were quantified by hazard ratios (HR) and confidence intervals (CI) from proportional hazards regression models; covariates included age, race, stage, grade, histologic subtype, and year of diagnosis.
resultsABO phenotype (N = 694) and/or genotype (N = 154) data were available for 713 predominantly Caucasian (89.3%) cases. In multivariable models, blood type A had significantly better OS compared to either O (HR: 0.75, 95% CI: 0.60-0.93) or all non-A (HR: 0.77, 95% CI: 0.63-0.94) cases. Similarly, missense rs1053878 minor allele carriers (A2) had better OS (HR: 0.50, 95% CI: 0.25-0.99). Among Caucasians, this phenotype association was strengthened, but the genotype association was attenuated; instead, four variants sharing moderate linkage disequilibrium with the O variant were associated with better OS (HR: 0.62, 95% CI: 0.39-0.99) in unadjusted models.
conclusionsBlood type A was significantly associated with longer ovarian cancer survival in the largest such study to date. This finding was supported by genetic analysis, which implicated the A2 allele, although O related variants also had suggestive associations. Further research on ABO and ovarian cancer survival is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.